Loading…

New pricing models for generic medicines to ensure long-term sustainable competition in Europe

Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2023-10, Vol.14, p.1200641-1200641
Main Authors: Francois, Clement, Gawlik, Gabriela, Mestre-Ferrandiz, Jorge, Pana, Adrian, Perelman, Julian, Yfantopoulos, John, Simoens, Steven
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c397t-7cfbac3d784c60ba84ff3b3f9665a0a460c851b85cb3475fb54f1ebb3e6d3443
container_end_page 1200641
container_issue
container_start_page 1200641
container_title Frontiers in pharmacology
container_volume 14
creator Francois, Clement
Gawlik, Gabriela
Mestre-Ferrandiz, Jorge
Pana, Adrian
Perelman, Julian
Yfantopoulos, John
Simoens, Steven
description Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector. Methods: A targeted literature review, one-to-one interviews and a joint advisory board meeting with experts from five European countries were carried out to assess potential pricing models for generic medicines. Results: We identified ten pricing models that can be applied to generic medicines. The tiered pricing model is viewed as a sustainable solution ensuring competitiveness, but requires market monitoring using a supportive IT infrastructure. De-linking the price of generic medicines from that of the off-patent originator medicine prevents the originator from forcing generic medicines’ prices to unsustainable levels. Higher costs due to inflation can be compensated in the automatic indexation model. Other pricing models that have less implementation potential include the one-in-one/multiple-out model, tax credits, value-based pricing, volume for savings and guaranteed margin/fee models. The hypothecated tax and cost allocation models, which add a patient fee to generic medicines prices, are not likely to be socially acceptable. Conclusion: When considering a new pricing model for generic medicines, the impact on innovative medicines and the characteristics of the healthcare system in a given country need to be taken into account. Also, there is a need to continuously follow up the level of competition in off-patent medicines markets and to identify sustainability risks.
doi_str_mv 10.3389/fphar.2023.1200641
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d6f634cc57d6489f86c1fa0207681d94</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d6f634cc57d6489f86c1fa0207681d94</doaj_id><sourcerecordid>2881713384</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-7cfbac3d784c60ba84ff3b3f9665a0a460c851b85cb3475fb54f1ebb3e6d3443</originalsourceid><addsrcrecordid>eNpVkUFL5TAQgIu4oKh_YE857qXPpEnT5LSI6CqIe_G8IUknNdImNUkV__22vseyzmWGmeEbhq-qvhO8o1TISzc_67RrcEN3pMGYM3JUnRLOaS0FaY7_q0-qi5xf8BpUSsrZafXnEd7RnLz1YUBT7GHMyMWEBgiwdtEE_TaDjEpEEPKSAI0xDHWBNKG85KJ90GYEZOM0Q_HFx4B8QDdLijOcV9-cHjNcHPJZ9XR783R9Vz_8_nV_ffVQWyq7UnfWGW1p3wlmOTZaMOeooU5y3mqsGcdWtMSI1hrKutaZljkCxlDgPWWMnlX3e2wf9Yta35l0-lBRe_XZiGlQOhVvR1A9d5wya9uu50xIJ7glTuMGd1yQXm6sn3vWvJj1ewuhJD1-gX6dBP-shvimCG4lZaRdCT8OhBRfF8hFTT5bGEcdIC5ZNUKQjqzqtmPNftWmmHMC9-8OwWqTqz7lqk2uOsilfwEHNZsp</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2881713384</pqid></control><display><type>article</type><title>New pricing models for generic medicines to ensure long-term sustainable competition in Europe</title><source>Open Access: PubMed Central</source><creator>Francois, Clement ; Gawlik, Gabriela ; Mestre-Ferrandiz, Jorge ; Pana, Adrian ; Perelman, Julian ; Yfantopoulos, John ; Simoens, Steven</creator><creatorcontrib>Francois, Clement ; Gawlik, Gabriela ; Mestre-Ferrandiz, Jorge ; Pana, Adrian ; Perelman, Julian ; Yfantopoulos, John ; Simoens, Steven</creatorcontrib><description>Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector. Methods: A targeted literature review, one-to-one interviews and a joint advisory board meeting with experts from five European countries were carried out to assess potential pricing models for generic medicines. Results: We identified ten pricing models that can be applied to generic medicines. The tiered pricing model is viewed as a sustainable solution ensuring competitiveness, but requires market monitoring using a supportive IT infrastructure. De-linking the price of generic medicines from that of the off-patent originator medicine prevents the originator from forcing generic medicines’ prices to unsustainable levels. Higher costs due to inflation can be compensated in the automatic indexation model. Other pricing models that have less implementation potential include the one-in-one/multiple-out model, tax credits, value-based pricing, volume for savings and guaranteed margin/fee models. The hypothecated tax and cost allocation models, which add a patient fee to generic medicines prices, are not likely to be socially acceptable. Conclusion: When considering a new pricing model for generic medicines, the impact on innovative medicines and the characteristics of the healthcare system in a given country need to be taken into account. Also, there is a need to continuously follow up the level of competition in off-patent medicines markets and to identify sustainability risks.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2023.1200641</identifier><language>eng</language><publisher>Frontiers Media S.A</publisher><subject>competition ; Europe ; generic medicines ; Pharmacology ; pricing ; sustainability</subject><ispartof>Frontiers in pharmacology, 2023-10, Vol.14, p.1200641-1200641</ispartof><rights>Copyright © 2023 Francois, Gawlik, Mestre-Ferrandiz, Pana, Perelman, Yfantopoulos and Simoens. 2023 Francois, Gawlik, Mestre-Ferrandiz, Pana, Perelman, Yfantopoulos and Simoens</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c397t-7cfbac3d784c60ba84ff3b3f9665a0a460c851b85cb3475fb54f1ebb3e6d3443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593415/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593415/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Francois, Clement</creatorcontrib><creatorcontrib>Gawlik, Gabriela</creatorcontrib><creatorcontrib>Mestre-Ferrandiz, Jorge</creatorcontrib><creatorcontrib>Pana, Adrian</creatorcontrib><creatorcontrib>Perelman, Julian</creatorcontrib><creatorcontrib>Yfantopoulos, John</creatorcontrib><creatorcontrib>Simoens, Steven</creatorcontrib><title>New pricing models for generic medicines to ensure long-term sustainable competition in Europe</title><title>Frontiers in pharmacology</title><description>Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector. Methods: A targeted literature review, one-to-one interviews and a joint advisory board meeting with experts from five European countries were carried out to assess potential pricing models for generic medicines. Results: We identified ten pricing models that can be applied to generic medicines. The tiered pricing model is viewed as a sustainable solution ensuring competitiveness, but requires market monitoring using a supportive IT infrastructure. De-linking the price of generic medicines from that of the off-patent originator medicine prevents the originator from forcing generic medicines’ prices to unsustainable levels. Higher costs due to inflation can be compensated in the automatic indexation model. Other pricing models that have less implementation potential include the one-in-one/multiple-out model, tax credits, value-based pricing, volume for savings and guaranteed margin/fee models. The hypothecated tax and cost allocation models, which add a patient fee to generic medicines prices, are not likely to be socially acceptable. Conclusion: When considering a new pricing model for generic medicines, the impact on innovative medicines and the characteristics of the healthcare system in a given country need to be taken into account. Also, there is a need to continuously follow up the level of competition in off-patent medicines markets and to identify sustainability risks.</description><subject>competition</subject><subject>Europe</subject><subject>generic medicines</subject><subject>Pharmacology</subject><subject>pricing</subject><subject>sustainability</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUFL5TAQgIu4oKh_YE857qXPpEnT5LSI6CqIe_G8IUknNdImNUkV__22vseyzmWGmeEbhq-qvhO8o1TISzc_67RrcEN3pMGYM3JUnRLOaS0FaY7_q0-qi5xf8BpUSsrZafXnEd7RnLz1YUBT7GHMyMWEBgiwdtEE_TaDjEpEEPKSAI0xDHWBNKG85KJ90GYEZOM0Q_HFx4B8QDdLijOcV9-cHjNcHPJZ9XR783R9Vz_8_nV_ffVQWyq7UnfWGW1p3wlmOTZaMOeooU5y3mqsGcdWtMSI1hrKutaZljkCxlDgPWWMnlX3e2wf9Yta35l0-lBRe_XZiGlQOhVvR1A9d5wya9uu50xIJ7glTuMGd1yQXm6sn3vWvJj1ewuhJD1-gX6dBP-shvimCG4lZaRdCT8OhBRfF8hFTT5bGEcdIC5ZNUKQjqzqtmPNftWmmHMC9-8OwWqTqz7lqk2uOsilfwEHNZsp</recordid><startdate>20231009</startdate><enddate>20231009</enddate><creator>Francois, Clement</creator><creator>Gawlik, Gabriela</creator><creator>Mestre-Ferrandiz, Jorge</creator><creator>Pana, Adrian</creator><creator>Perelman, Julian</creator><creator>Yfantopoulos, John</creator><creator>Simoens, Steven</creator><general>Frontiers Media S.A</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20231009</creationdate><title>New pricing models for generic medicines to ensure long-term sustainable competition in Europe</title><author>Francois, Clement ; Gawlik, Gabriela ; Mestre-Ferrandiz, Jorge ; Pana, Adrian ; Perelman, Julian ; Yfantopoulos, John ; Simoens, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-7cfbac3d784c60ba84ff3b3f9665a0a460c851b85cb3475fb54f1ebb3e6d3443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>competition</topic><topic>Europe</topic><topic>generic medicines</topic><topic>Pharmacology</topic><topic>pricing</topic><topic>sustainability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Francois, Clement</creatorcontrib><creatorcontrib>Gawlik, Gabriela</creatorcontrib><creatorcontrib>Mestre-Ferrandiz, Jorge</creatorcontrib><creatorcontrib>Pana, Adrian</creatorcontrib><creatorcontrib>Perelman, Julian</creatorcontrib><creatorcontrib>Yfantopoulos, John</creatorcontrib><creatorcontrib>Simoens, Steven</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Francois, Clement</au><au>Gawlik, Gabriela</au><au>Mestre-Ferrandiz, Jorge</au><au>Pana, Adrian</au><au>Perelman, Julian</au><au>Yfantopoulos, John</au><au>Simoens, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New pricing models for generic medicines to ensure long-term sustainable competition in Europe</atitle><jtitle>Frontiers in pharmacology</jtitle><date>2023-10-09</date><risdate>2023</risdate><volume>14</volume><spage>1200641</spage><epage>1200641</epage><pages>1200641-1200641</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Background: Price erosion of generic medicines over time as a result of existing pricing policies in combination with increasing operational costs of these products due to high inflation, undermine long-term sustainable competition in European off-patent medicines markets. Therefore, the aim of this study is to identify new potential pricing models for retail generic medicines in Europe, examine their pros and cons, and illustrate them with examples inside or outside the pharmaceutical sector. Methods: A targeted literature review, one-to-one interviews and a joint advisory board meeting with experts from five European countries were carried out to assess potential pricing models for generic medicines. Results: We identified ten pricing models that can be applied to generic medicines. The tiered pricing model is viewed as a sustainable solution ensuring competitiveness, but requires market monitoring using a supportive IT infrastructure. De-linking the price of generic medicines from that of the off-patent originator medicine prevents the originator from forcing generic medicines’ prices to unsustainable levels. Higher costs due to inflation can be compensated in the automatic indexation model. Other pricing models that have less implementation potential include the one-in-one/multiple-out model, tax credits, value-based pricing, volume for savings and guaranteed margin/fee models. The hypothecated tax and cost allocation models, which add a patient fee to generic medicines prices, are not likely to be socially acceptable. Conclusion: When considering a new pricing model for generic medicines, the impact on innovative medicines and the characteristics of the healthcare system in a given country need to be taken into account. Also, there is a need to continuously follow up the level of competition in off-patent medicines markets and to identify sustainability risks.</abstract><pub>Frontiers Media S.A</pub><doi>10.3389/fphar.2023.1200641</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2023-10, Vol.14, p.1200641-1200641
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d6f634cc57d6489f86c1fa0207681d94
source Open Access: PubMed Central
subjects competition
Europe
generic medicines
Pharmacology
pricing
sustainability
title New pricing models for generic medicines to ensure long-term sustainable competition in Europe
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A09%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20pricing%20models%20for%20generic%20medicines%20to%20ensure%20long-term%20sustainable%20competition%20in%20Europe&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Francois,%20Clement&rft.date=2023-10-09&rft.volume=14&rft.spage=1200641&rft.epage=1200641&rft.pages=1200641-1200641&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2023.1200641&rft_dat=%3Cproquest_doaj_%3E2881713384%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c397t-7cfbac3d784c60ba84ff3b3f9665a0a460c851b85cb3475fb54f1ebb3e6d3443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2881713384&rft_id=info:pmid/&rfr_iscdi=true